NYXH
Price
$0.90Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
86.12M
133 days until earnings call
Intraday BUY SELL Signals
RGEN
Price
$172.62Alerts
Change
-$1.36 (-0.78%)
Updated
Nov 11 closing price
Capitalization
9.79B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NYXH vs RGEN

NYXH vs RGEN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NYXH vs. RGEN commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NYXH is a Buy and RGEN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NYXH with price predictions
Nov 11, 2026

NYXH's RSI Indicator ascending out of oversold territory

The RSI Indicator for NYXH moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 71 cases where NYXH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on NYXH as a result. In 68 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for NYXH just turned positive on November 03, 2026. Looking at past instances where NYXH's MACD turned positive, the stock continued to rise in 27 of 49 cases over the following month. The odds of a continued upward trend are 55%.

Following a +0.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where NYXH advanced for three days, in 144 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

NYXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NYXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for NYXH entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.036) is normal, around the industry mean (4.142). P/E Ratio (-0.386) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.746) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. NYXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NYXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RGEN with price predictions
Nov 11, 2026

RGEN in downward trend: price dove below 50-day moving average on November 10, 2026

RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 57 cases where RGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 71 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
RGEN: Fundamental Ratings
RGEN
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
88
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NYXHRGEN
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
75%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (NYXH: $0.90 vs. RGEN: $172.62)
Brand notoriety: NYXH and RGEN are both not notable
NYXH represents the Medical/Nursing Services, while RGEN is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: NYXH: 144% vs. RGEN: 76%
Market capitalization -- NYXH: $86.12M vs. RGEN: $9.79B
NYXH [@Medical/Nursing Services] is valued at $86.12M. RGEN’s [@Pharmaceuticals: Other] market capitalization is $9.79B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NYXH’s FA Score shows that 1 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).

  • NYXH’s FA Score: 1 green, 4 red.
  • RGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, NYXH is a better buy in the long-term than RGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NYXH’s TA Score shows that 6 TA indicator(s) are bullish while RGEN’s TA Score has 2 bullish TA indicator(s).

  • NYXH’s TA Score: 6 bullish, 2 bearish.
  • RGEN’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, NYXH is a better buy in the short-term than RGEN.

Price Growth

NYXH (@Medical/Nursing Services) experienced а +4.72% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -3.13% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.76%. For the same industry, the average monthly price growth was -4.63%, and the average quarterly price growth was -1.72%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.07%. For the same industry, the average monthly price growth was +6.43%, and the average quarterly price growth was +22.77%.

Reported Earning Dates

NYXH is expected to report earnings on Mar 25, 2027.

RGEN is expected to report earnings on Feb 24, 2027.

Industries' Descriptions

@Medical/Nursing Services (-2.76% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (+2.07% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

NYXH and

Correlation & Price change

A.I.dvisor indicates that over the last year, NYXH has been loosely correlated with NUWE. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NYXH jumps, then NUWE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NYXH
1D Price
Change %
NYXH100%
+0.01%
NUWE - NYXH
35%
Loosely correlated
+5.53%
TXG - NYXH
27%
Poorly correlated
-1.35%
CLPT - NYXH
26%
Poorly correlated
+4.56%
RGEN - NYXH
26%
Poorly correlated
-0.78%
PROF - NYXH
25%
Poorly correlated
+2.21%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DUOG63.065.61
+9.77%
Leverage Shares 2X Long DUOL Daily ETF (DUOG)
HTAX23.780.05
+0.21%
Macquarie National High-Yield Municipal Bond ETF
SLVO54.760.09
+0.17%
UBS AG ETRACS Silver Shares Covered Call ETNs due April 21, 2033 ETP 2022-21.04.33 on CS NQ Slv FLS106 Pr (SLVO)
EVSD50.04-0.03
-0.06%
Eaton Vance Short Duration Income ETF (EVSD)
QQQD12.31-0.06
-0.53%
Direxion Daily Concentrated Qs Bear 1X Shares